Two-year results of the Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial show that transcatheter aortic valve replacement with Medtronic PLC's CoreValve or CoreValve Evolut R is noninferior to surgical valve replacement in patients with aortic stenosis at intermediate risk of complications during surgery.
"We made our two-year non-inferiority endpoint with very strong statistics," SURTAVI's lead investigator, surgeon Michael Reardon of Houston Methodist DeBakey Heart & Vascular Center, told Medtech Insight. Reardon presented the...